Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Pediatric Endocrinology

The Genetic Roots of Rapid Growth

At a Glance

At specialized centers, genetic changes are found in up to half of children with pituitary gigantism. AIP mutations, GPR101 duplication causing X-LAG, and syndromes such as MEN1 or MEN4 can affect tumor behavior, treatment choices, and whether relatives need screening.

While most adults with growth hormone issues have no clear genetic link, children are different. In pediatric pituitary gigantism, up to half of cases seen at specialized centers are caused by a specific genetic change [1][2].

It is important to understand that “genetic” does not always mean “inherited.” Many children have a de novo mutation—a spontaneous change that occurred only in them and was not passed down by a parent [3][4]. Identifying these genetic markers is vital because it helps doctors anticipate how the condition might behave and which treatments may be considered [5].

AIP Mutations

A frequently identified genetic link in some cohorts is a mutation in the AIP (Aryl Hydrocarbon Receptor-Interacting Protein) gene [1]. This is often part of a condition called Familial Isolated Pituitary Adenoma (FIPA) [6].

  • Tumor Behavior: AIP-related tumors tend to appear at a very young age and are often macroadenomas (tumors larger than 10mm) [7][8].
  • Incomplete Penetrance: AIP mutations are autosomal dominant, but they have incomplete penetrance. A positive result does not mean every family member who carries the gene will develop a tumor.
  • Treatment Considerations: These tumors are sometimes less responsive to standard medications called somatostatin analogues [8][9]. If an AIP mutation is found, your care team might consider alternative approaches [10].

X-LAG: Growth Starting in Infancy

X-linked acrogigantism, or X-LAG, is a unique and rare form of gigantism caused by a duplication of genetic material on the X chromosome (specifically the GPR101 gene) [11].

  • Early Onset: Unlike other forms, X-LAG almost always begins in very early infancy—often before a child is 2 years old [12][13].
  • Rapid Growth: These children experience very rapid growth and often have very high levels of both growth hormone and prolactin (a hormone involved in milk production) [12][14].
  • Complex Testing: In some boys, the genetic change only exists in some cells of the body (mosaicism). This means a standard blood test might come back negative even if the child has the condition; in these cases, testing a small sample of the tumor tissue itself may be necessary for a diagnosis [3][15].

Other Syndromic Causes

Sometimes, a pituitary tumor is one part of a larger syndrome that affects multiple organs.

  • Multiple Endocrine Neoplasia Type 1 (MEN1) & Type 4 (MEN4): These conditions can cause tumors in the pituitary, parathyroid, and pancreas [16][17].
  • Carney Complex: This syndrome may involve pituitary tumors along with spotty skin pigmentation (lentigines) and tumors of the heart (myxomas) or adrenal glands [18][19].
  • McCune-Albright Syndrome (MAS): This is caused by a mutation that occurs early in development. It often presents with large “café-au-lait” skin spots with irregular borders and a bone condition called fibrous dysplasia [20][21].

The Role of Genetic Testing

Because the genetic link is so strong, expert guidelines recommend genetic evaluation for children diagnosed with growth hormone excess and large pituitary tumors [5][22].

This process usually begins with a meeting with a genetic counselor to review your family history. Testing typically involves a blood or saliva sample. A positive result is not a “bad omen”—rather, it is a tool that allows your medical team to tailor the treatment plan and informs whether other family members should be screened early [23][24].

Common questions in this guide

What genetic causes are linked to pituitary gigantism?
The main genetic links discussed are changes in AIP, duplication of GPR101 causing X-linked acrogigantism, and syndromes such as MEN1, MEN4, Carney complex, and McCune-Albright syndrome. The appropriate tests depend on the child’s age at onset, tumor size, and other physical or family findings.
Does pituitary gigantism always run in families?
No. Some genetic changes are inherited, but many are de novo, meaning they occur in the child and were not passed down by a parent. An AIP change can be inherited, but not everyone who carries it develops a pituitary tumor.
What does an AIP mutation mean for treatment?
AIP-related tumors often begin at a young age, are large, and may respond less well to somatostatin analogue medicines. If an AIP change is found, the care team may consider other treatment approaches when planning care.
Can a blood test miss X-LAG?
Yes. In some boys, the GPR101 change is present in only some cells, so a blood test may not detect it. If a child’s rapid growth and other findings strongly suggest X-LAG, clinicians may consider testing tumor tissue.
When is genetic testing recommended for a child with pituitary gigantism?
Expert guidelines recommend genetic evaluation for children with growth hormone excess and a large pituitary tumor. Testing often uses blood or saliva, and a genetic counselor can review the child’s history and family history before testing.
Should family members be tested if a genetic change is found?
It depends on the gene or syndrome and the family’s medical history. A genetic counselor can explain which relatives may benefit from testing or earlier monitoring, while also explaining that some mutations do not cause tumors in every person who carries them.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the age of onset and tumor size, which specific genetic tests (like AIP or GPR101) do you recommend first?
  2. 2.If an AIP mutation is found, how does that inform the treatment decisions?
  3. 3.Does a 'negative' genetic test from a blood sample completely rule out a genetic cause, or should we consider testing other tissues if symptoms are classic?
  4. 4.How do we decide if other family members, including siblings, need to be screened or tested?
  5. 5.If a genetic syndrome like MEN1 or Carney Complex is suspected, what other parts of the body need to be monitored?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients.

    Rostomyan L, Daly AF, Petrossians P, et al.

    Endocrine-related cancer 2015; (22(5)):745-57 doi:10.1530/ERC-15-0320.

    PMID: 26187128
  2. 2

    Genetics of Acromegaly and Gigantism.

    Bogusławska A, Korbonits M

    Journal of clinical medicine 2021; (10(7)) doi:10.3390/jcm10071377.

    PMID: 33805450
  3. 3

    Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects.

    Daly AF, Yuan B, Fina F, et al.

    Endocrine-related cancer 2016; (23(4)):221-33 doi:10.1530/ERC-16-0082.

    PMID: 26935837
  4. 4

    The Spectrum of Familial Pituitary Neuroendocrine Tumors.

    Armeni E, Grossman A

    Endocrine pathology 2023; (34(1)):57-78 doi:10.1007/s12022-022-09742-0.

    PMID: 36401106
  5. 5

    Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases.

    Korbonits M, Blair JC, Boguslawska A, et al.

    Nature reviews. Endocrinology 2024; (20(5)):290-309 doi:10.1038/s41574-023-00949-7.

    PMID: 38336898
  6. 6

    HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The roles of AIP and GPR101 in familial isolated pituitary adenomas (FIPA).

    Vasilev V, Daly AF, Trivellin G, et al.

    Endocrine-related cancer 2020; (27(8)):T77-T86.

    PMID: 32083999
  7. 7

    Risk category system to identify pituitary adenoma patients with AIP mutations.

    Caimari F, Hernández-Ramírez LC, Dang MN, et al.

    Journal of medical genetics 2018; (55(4)):254-260 doi:10.1136/jmedgenet-2017-104957.

    PMID: 29440248
  8. 8

    Germline AIP variants in sporadic young acromegaly and pituitary gigantism: clinical and genetic insights from a Han Chinese cohort.

    Xiang B, Zhang X, Liu W, et al.

    Endocrine 2024; (85(3)):1346-1356 doi:10.1007/s12020-024-03898-x.

    PMID: 38851643
  9. 9

    AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients.

    Daly AF, Rostomyan L, Betea D, et al.

    Endocrine connections 2019; (8(4)):367-377.

    PMID: 30851160
  10. 10

    Complicated Clinical Course in Incipient Gigantism Due to Treatment-resistant Aryl Hydrocarbon Receptor-Interacting Protein-mutated Pediatric Somatotropinoma.

    van Santen SS, Daly AF, Buchfelder M, et al.

    AACE clinical case reports 2022; (8(3)):119-123 doi:10.1016/j.aace.2021.12.003.

    PMID: 35602875
  11. 11

    Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism.

    Franke M, Daly AF, Palmeira L, et al.

    American journal of human genetics 2022; (109(4)):553-570 doi:10.1016/j.ajhg.2022.02.002.

    PMID: 35202564
  12. 12

    X-linked acrogigantism syndrome: clinical profile and therapeutic responses.

    Beckers A, Lodish MB, Trivellin G, et al.

    Endocrine-related cancer 2015; (22(3)):353-67 doi:10.1530/ERC-15-0038.

    PMID: 25712922
  13. 13

    Genome architecture in endocrine diseases: X-linked acrogigantism (X-LAG) syndrome.

    Daly AF, Beckers A, Pétrossians P

    Annales d'endocrinologie 2026; (87(2)):102511 doi:10.1016/j.ando.2026.102511.

    PMID: 41887597
  14. 14

    Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study.

    Iacovazzo D, Caswell R, Bunce B, et al.

    Acta neuropathologica communications 2016; (4(1)):56 doi:10.1186/s40478-016-0328-1.

    PMID: 27245663
  15. 15

    Somatic GPR101 Duplication Causing X-Linked Acrogigantism (XLAG)-Diagnosis and Management.

    Rodd C, Millette M, Iacovazzo D, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(5)):1927-30 doi:10.1210/jc.2015-4366.

    PMID: 26982009
  16. 16

    A Pituitary Macroadenoma Cosecreting Prolactin and Growth Hormone in a Patient With Multiple Endocrine Neoplasia Type 4.

    Green L, Simpson M, Bahri A, et al.

    JCEM case reports 2025; (3(7)):luaf124 doi:10.1210/jcemcr/luaf124.

    PMID: 40443455
  17. 17

    GHRH and insulin hypersecretion from a pancreatic neuroendocrine tumor in multiple endocrine neoplasia type 1.

    Lamback E, Bulzico DA, Lourenço DM, et al.

    JCEM case reports 2026; (4(4)):luag002 doi:10.1210/jcemcr/luag002.

    PMID: 42007244
  18. 18

    Carney Complex.

    Kamilaris CDC, Faucz FR, Voutetakis A, Stratakis CA

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2019; (127(2-03)):156-164 doi:10.1055/a-0753-4943.

    PMID: 30428497
  19. 19

    Cushing's syndrome and early growth hormone hypersecretion in a child with Carney complex: a case report.

    Pietropaolo G, Festa A, Rivetti G, et al.

    Frontiers in endocrinology 2026; (17()):1843310 doi:10.3389/fendo.2026.1843310.

    PMID: 42445874
  20. 20

    Safe Continuation of Pegvisomant During Pregnancy in a Patient With Fibrous Dysplasia/McCune-Albright Syndrome.

    Tan JY, Chemmanam J, Burt MG, et al.

    JCEM case reports 2025; (3(6)):luaf095 doi:10.1210/jcemcr/luaf095.

    PMID: 40365550
  21. 21

    McCune-Albright syndrome and type 1 diabetes mellitus: a novel presentation.

    Chatty P, Khattab A, Marshall I

    Annals of the New York Academy of Sciences 2020; (1463(1)):5-8 doi:10.1111/nyas.14310.

    PMID: 32037600
  22. 22

    Diagnosis and management of pituitary adenomas in children and adolescents.

    Maiter D, Chanson P, Constantinescu SM, Linglart A

    European journal of endocrinology 2024; (191(4)):R55-R69 doi:10.1093/ejendo/lvae120.

    PMID: 39374844
  23. 23

    Genetics of familial acromegaly and pituitary gigantism.

    De Sousa SMC, Daly AF

    The Journal of clinical endocrinology and metabolism 2026; (111(Supplement_1)):S13-S26 doi:10.1210/clinem/dgag151.

    PMID: 41965096
  24. 24

    Pituitary Disease in AIP Mutation-Positive Familial Isolated Pituitary Adenoma (FIPA): A Kindred-Based Overview.

    Bilbao Garay I, Daly AF, Egaña Zunzunegi N, Beckers A

    Journal of clinical medicine 2020; (9(6)) doi:10.3390/jcm9062003.

    PMID: 32604740

This page is for informational purposes only and does not constitute medical advice. Genetic testing and treatment decisions should be discussed with your child’s medical team and a genetic counselor.

Get notified when new evidence is published on Pituitary gigantism.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.